Kintara Therapeutics, Inc. Price Today
Kintara Therapeutics, Inc.
KTRA
Healthcare
$6.87M
💰
Market Cap
0
💸
Price to Earnings
$-11.3
🎉
EPS
+0
🌳
ESG
Consensus Recommendations
Buy Consensus
Buy |
4 |
Strong Buy |
2 |
Hold |
2 |
Sell |
0 |
Strong Sell |
0 |
KTRA Price Forecast Target
4.1 👉 14.0 +245%
KTRA EPS Forecast
-11.3 👉 -1.1 +-91%
Financials
Profit Margin
0 %
Revenue Growth
0 %
Dividend
$ 0
Held Percent
4.2% - Insiders
3.3% - Institutions
92.5% - Public
Major Fund Holders
-
💰 Geode Capital Management, LLC $49,533.0
-
💰 State Street Corporation $37,834.0
-
💰 Susquehanna International Group, LLP $37,626.0
-
💰 Acadian Asset Management. LLC $22,867.0
-
💰 Morgan Stanley $11,808.0
Stock Ideas
Nancy Pelosi Portfolio
Nancy Pelosi is the Speaker of the United States House of Representatives and a savvy investor. Her personal portfolio is heavily weighted towards large-cap tech stocks, such as Apple and Microsoft. She also owns shares in several consumer staples a…
Christopher Hohn Portfolio
Christopher Hohn is a British hedge fund manager and philanthropist. He founded The Children's Investment Fund Management in 2003, one of Europe's largest hedge funds. Known for his activist investment approach, Hohn targets undervalued companies wi…
Stephen Mandel Portfolio
Stephen Mandel is the founder and portfolio manager of Lone Pine Capital, one of the largest and most successful hedge funds. Employing rigorous fundamental analysis, Mandel searches globally for qualitatively excellent growth companies trading at r…
Steven Cohen Portfolio
Steven Cohen, the legendary trader and billionaire founder of Stamford-based SAC Capital, has established himself as a force to be reckoned with in the hedge fund industry. With a staggering net worth of $8 billion and an impressive $14 billion in …📮FAQ
Some Frequently Asked Questions.
The Kintara Therapeutics, Inc. industry is Biotechnology
The Kintara Therapeutics, Inc. sector is Healthcare
The Kintara Therapeutics, Inc. forecasted predicted Price to Earnings PE ratio is -3.8
The Kintara Therapeutics, Inc. Price to Earnings PE ratio is 0
The Market Capitalization of Kintara Therapeutics, Inc. is $6.87M
There are total of 1658264 float shares with 3.3% held by Institutions and 4.2% held by insiders
The MKintara Therapeutics, Inc. forecasted Earnings per Share EPS is $-1.1
The Kintara Therapeutics, Inc. Earnings per Share EPS is -11.3
The Kintara Therapeutics, Inc. company has $0 gross profits with 0 profit margins
The Kintara Therapeutics, Inc. Earnings Growth is 0% with 0% quarterly earnings growth
The Kintara Therapeutics, Inc. Revenue is $0 with 0 revenue growth
The price target for Kintara Therapeutics, Inc. stock is $14.0 for the high target and $14.0 for the low target
The consensus analyst recommendations for Kintara Therapeutics, Inc. is Buy, however the decision to buy or sell the stock should be entirely yours, as you are earning your own money and hence responsible on how to allocate and spend them.
The consensus analyst recommendations for Kintara Therapeutics, Inc. is Buy, with the following breakdown:
- Buy: 4
- Strong Buy: 2
- Hold: 2
- Sell: 0
- Strong Sell: 0
The Beta of Kintara Therapeutics, Inc. is 1.0
The dividend of Kintara Therapeutics, Inc. is $0
The dividend yield of Kintara Therapeutics, Inc. is 0%
The biggest institutional and mutual fund holders of Kintara Therapeutics, Inc. stock are
- Geode Capital Management, LLC
- State Street Corporation
- Susquehanna International Group, LLP
- Acadian Asset Management. LLC
The Kintara Therapeutics, Inc. ESG Score is 0, with the following breakdown:
- E: 0
- S: 0
- G: 0